New patient-centric solution for the management of chronic respiratory insufficiency diseases

November 16, 2012

Philips Respironics today announces the availability of the new bi-level ventilator BiPAP A401 for the management of chronic respiratory insufficiency, a condition secondary to diseases such as obesity hypoventilation syndrome, chronic obstructive pulmonary disease (COPD) and neuromuscular disease for adult and pediatric patients (above 10 kg).

Launching on World COPD Day 2012 and being showcased this week at Medica 2012, the world's largest medical trade fair, the BiPAP A40 improves the management of chronic respiratory diseases by offering a range of unique benefits that facilitate the smoothest possible transition in the patient care pathway – from initial titration to , from home therapy to long-term follow-up.

"Philips is proud to be able to provide access to new and innovative solutions that improve quality of care for respiratory patients – both in hospital and at home," comments Mats Dahlquist, general manager international, Philips Home Healthcare Solutions.

One of the key benefits of the BiPAP A40 is an innovative ventilation mode called AVAPS-AE, which helps to guide clinicians during the initial titration of therapy, while maintaining comfort and improving efficacy for the patient. This new ventilation mode automatically maintains airway patency while delivering the correct level of ventilation each user requires, whatever their body position or sleep stage. AVAPS-AE mode also helps to guide clinicians during the initial titration of therapy, while providing long term comfort and assuring therapy compliance.

In addition to the introduction of AVAPS-AE, the BiPAP A40 features a unique battery module design which provides users with an enhanced level of autonomy that increases support when traveling, or in the case of a power shortage. Furthermore, the design incorporates an intuitive user interface and data management tools that allow clinicians to remotely access and review data about a user's therapy, adjusting it as necessary. This can help to reduce therapy drop out and the associated risk of hospital re-admission.

Although many are preventable and can be effectively managed, they continue to be an important cause of morbidity, mortality and the increased health care costs worldwide. COPD is predicted to become the third leading cause of death worldwide by 2030, with 65 million people currently living with the disease across the world. "COPD is a particularly costly disease to manage, with an annual healthcare bill of more than 10 billion Euros across the EU alone."

More information: Wouters EFM. Economic analysis of the confronting COPD survey: an overview of results. Respir Med 2003; 97:S3-S14.
www.philips.com/BiPAP

Related Stories

Miniature ventilator may help COPD patients improve mobility

May 16, 2011

A miniature, easy-to-carry ventilation system with a simple nasal mask may help patients with chronic obstructive pulmonary disease (COPD) become more active, according to research conducted at medical centers in California ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.